Payers Reluctant To Leverage Comparative Effectiveness To Deny Coverage
This article was originally published in The Pink Sheet Daily
Just learning about the results of comparative studies does not move payers to deny coverage of targeted services based on the experiences so far of the New England Comparative Effectiveness Public Advisory Council.
You may also be interested in...
An ambitious effort is gearing up to adapt federal comparative effectiveness research into an easy-to-understand and useful tool for New England payers, providers, patients and policy-makers.
FDA Open To Home COVID-19 Testing With Caveats, OIVD’s Stenzel Says; Grants First Serology Test EUA To BD
The US FDA is open to the idea of home-testing for the COVID-19 virus, but only after making sure the test is completely safe and effective, and available only through a physician’s oversight, said Tim Stenzel, director of the agency’s Office of In Vitro Diagnostics and Radiological Health. Stenzel also heralded the FDA’s first emergency use authorization for a coronavirus serology test, which was granted to diagnostic developer Becton Dickinson.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.